Welcome to LookChem.com Sign In|Join Free
  • or
ethyl 4-(2-methoxy-5-nitrophenoxy)butanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1093798-74-3

Post Buying Request

1093798-74-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1093798-74-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1093798-74-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,7,9 and 8 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1093798-74:
(9*1)+(8*0)+(7*9)+(6*3)+(5*7)+(4*9)+(3*8)+(2*7)+(1*4)=203
203 % 10 = 3
So 1093798-74-3 is a valid CAS Registry Number.

1093798-74-3Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer

Chen, Jinying,Sang, Zitai,Jiang, Youjun,Yang, Chao,He, Linhong

, p. 232 - 241 (2018/11/02)

Fifty-eight quinazoline-based compounds were designed and synthesized based on the structural optimizations from the lead compound 23bb in an attempt to search for more potent dual HDAC1 and HDAC6 inhibitors. Among them, 32c (HDAC1, IC50?=?31.1

Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer

Yang, Zhuang,Wang, Taijin,Wang, Fang,Niu, Ting,Liu, Zhuowei,Chen, Xiaoxin,Long, Chaofeng,Tang, Minghai,Cao, Dong,Wang, Xiaoyan,Xiang, Wei,Yi, Yuyao,Ma, Liang,You, Jingsong,Chen, Lijuan

, p. 1455 - 1470 (2016/03/08)

Novel selective histone deacetylase 6 (HDAC6) inhibitors using the quinazoline as the cap were designed, synthesized, and evaluated for HDAC enzymatic assays. N-Hydroxy-4-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)butanamide, 23bb, was the

PYRROLOPYRIMIDINES

-

Page/Page column 50, (2009/03/07)

The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.

INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES

-

Page/Page column 66, (2009/01/23)

The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to certain indolin- 2-ones and aza-indolin-2-ones which possess anti-tumour activity and are accordingly useful in methods of treatment of the human or animal body, in particular such compounds are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1093798-74-3